Biotech Startup AIRNA Adds $60M to Advance RNA-Editing Therapy for Rare Protein Deficiency

Biotech startup AIRNA gained $60 million in a funding round to support its development of a genetic medicine for treating the deficiency of liver protein alpha-1 antitrypsin, a condition that damages the lungs and liver. The US-based company says the therapy, which edits RNA, could be superior to existing treatments. AIRNA plans to progress its alpha-1 antitrypsin deficiency program to clinical trials in 2025.